Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.76%172.501.1%$711.75m
GILDGilead Sciences, Inc.
0.09%70.540.9%$695.99m
CELGCelgene Corporation
0.47%134.311.1%$649.60m
REGNRegeneron Pharmaceuticals, Inc.
-1.75%517.332.7%$572.31m
ALXNAlexion Pharmaceuticals, Inc.
-0.13%126.071.9%$521.18m
BIIBBiogen Inc.
-0.09%280.321.2%$500.23m
VRTXVertex Pharmaceuticals Incorporated
-1.50%133.501.9%$279.31m
INCYIncyte Corporation
0.48%136.282.6%$278.87m
CLVSClovis Oncology, Inc.
-1.84%95.0018.0%$249.90m
TSROTESARO, Inc.
-2.16%146.5314.7%$249.01m
ILMNIllumina, Inc.
1.25%185.283.5%$164.61m
BLUEBluebird Bio, Inc.
-5.49%112.0019.3%$162.00m
PBYIPuma Biotechnology, Inc.
1.22%87.5021.1%$145.68m
KITEKite Pharma, Inc.
7.09%100.6616.1%$139.56m
EXASExact Sciences Corporation
2.31%35.5126.3%$130.55m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.,003DX0-E